1. Home
  2. NOAH vs STRO Comparison

NOAH vs STRO Comparison

Compare NOAH & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NOAH

Noah Holdings Limited

HOLD

Current Price

$10.26

Market Cap

653.4M

Sector

Finance

ML Signal

HOLD

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$31.08

Market Cap

524.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOAH
STRO
Founded
2005
2003
Country
China
United States
Employees
N/A
133
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
653.4M
524.8M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
NOAH
STRO
Price
$10.26
$31.08
Analyst Decision
Hold
Buy
Analyst Count
2
9
Target Price
$11.00
$31.33
AVG Volume (30 Days)
71.2K
265.8K
Earning Date
05-27-2026
05-11-2026
Dividend Yield
5.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.71
N/A
P/E Ratio
$13.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.53
$0.67
52 Week High
$12.84
$43.85

Technical Indicators

Market Signals
Indicator
NOAH
STRO
Relative Strength Index (RSI) 44.73 54.35
Support Level $9.83 $23.53
Resistance Level $10.77 $43.85
Average True Range (ATR) 0.27 2.84
MACD -0.00 0.54
Stochastic Oscillator 35.71 94.41

Price Performance

Historical Comparison
NOAH
STRO

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Share on Social Networks: